Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  imatinib mesylate
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0697, NCI-2013-00551, NCT01751425
Binimetinib and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-162, NCI-2013-02281, NCT01991379
BGJ398 and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumor
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-140, NCI-2014-02117, NCT02257541
Recombinant Interferon Alpha-2a and Sargramostim or Vaccine Therapy in Treating Patients with Chronic Phase Chronic Myelogenous Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J05121, NCI-2011-00392, CDR0000492005, JHOC-J05121, NA_00001887, NCT00363649
Open Label, Randomized Phase 2b Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who do Not Have Favorable Imatinib Response
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA180-399, NCI-2012-02781, 2011-006181-41, NCT01593254
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride with Asparaginase in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9459, NCI-2015-01402, CC9459, NCT02538926
Dasatinib or Nilotinib Followed by Imatinib Mesylate in Treating Patients with Newly Diagnosed, Previously Untreated, Chronic Phase Chronic Myeloid Leukemia
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 and over
Trial IDs: Winship3143-16, NCI-2016-00162, IRB00087045, NCT02709083
Ipilimumab and Imatinib Mesylate in Advanced Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 15 and over
Trial IDs: 2012-0784, NCI-2013-00030, NCT01738139
Start Over